Monopar Therapeutics Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Monopar Therapeutics Inc. (MNPR) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -0.66% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-03-27
- Monopar Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -0.66%.
- Monopar Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -2.81%.
- Monopar Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was -2.45%.
- Monopar Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was -1.97%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2024-12-31 | -0.66% 10-K · filed 2026-03-27 |
| 2023-12-31 | -2.81% 10-K · filed 2026-03-27 |
| 2022-12-31 | -2.45% 10-K · filed 2024-03-28 |
| 2021-12-31 | -1.97% 10-K · filed 2023-03-23 |
| 2020-12-31 | -1.56% 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |